Abstract

SARS-CoV2 infection enters via the nose and, after aspiration to the lower respiratory tract, may then rapidly involve the lungs, resulting in severe hypoxic pneumonia. In the later stage of coronavirus disease 2019 (COVID-19), there is also a cytokine-mediated hyperinflammatory response and coagulopathy, which in many respects simulates a viral-induced multiorgan autoimmune response.

Patients who tend to fare worse with more severe outcomes are males, elderly, smokers, black and Asian people, those with obesity, along with the presence of comorbidities such as diabetes, hypertension, chronic heart, lung and kidney disease, dementia, neoplasia, and immunosuppression.

Rights

© 2020 American Academy of Allergy, Asthma & Immunology

Cite as

Lipworth, B., Chan, R. & Kuo, C. 2020, 'Predicting severe outcomes in COVID-19', The Journal of Allergy and Clinical Immunology: In Practice, 8(8), pp. 2582-2584. https://doi.org/10.1016/j.jaip.2020.06.039

Downloadable citations

Download HTML citationHTML Download BIB citationBIB Download RIS citationRIS
Last updated: 16 September 2022
Was this page helpful?